Larimar Therapeutics, Inc.

Larimar Therapeutics Strengthens Executive Leadership with Appointment of John Harlow as President and Chief Operating Officer

Larimar Therapeutics appointed John Harlow as President and Chief Operating Officer, effective September 29, 2026, reporting to CEO Carole Ben-Maimon. Harlow brings more than 25 years of biopharma commercial and operational experience, most recently as Chief Commercial Officer of Esperion, with prior roles at Melinta, Baudax Bio, Recro Pharma, Endo, Novartis and Janssen. The hire signals launch-readiness for nomlabofusp, Larimar's lead candidate for Friedreich's ataxia, as the company nears potential accelerated approval and prepares to scale commercially. In connection with the appointment, Harlow received Nasdaq Rule 5635(c)(4) inducement awards: options on 800,000 shares vesting over four years and RSUs on 50,000 shares vesting annually over four years.

•26d ago

Larimar Therapeutics Reports Second Quarter 2026 Financial and Business Update

Larimar reported a Q2 net loss of $32.8 million, or $0.30 per share, while holding $156.3 million in cash and equivalents to fund operations into the third quarter of 2027. The company initiated a rolling BLA submission for nomlabofusp following a successful Type B FDA meeting, with full submission expected in the second half of 2026. Open-label study data showed sustained increases in skin frataxin levels and clinical improvements, with dosing of the first patient in the confirmatory Phase 3 study expected in Q3 2026.

•2mo ago

Larimar Therapeutics Reports Positive Open Label Data and Submission of First Module of Rolling BLA for Accelerated Approval of Nomlabofusp for Friedreich’s Ataxia

Larimar Therapeutics submitted the first module of a rolling Biologics License Application (BLA) to the FDA for accelerated approval of nomlabofusp in Friedreich’s ataxia, following FDA confirmation that the current data package appears sufficient for submission and review. Long-term open-label data showed that 100% of participants maintained skin frataxin (FXN) levels above 50% of healthy volunteer means at 1 year, while clinical outcome measures improved relative to a worsening natural history reference population. The company expects to submit the remaining BLA modules in the second half of 2026, initiate dosing in a confirmatory Phase 3 study in Q3 2026, and is targeting a mid-2027 launch if approved.

•3mo ago

LRMR: 10-Q · periodic report

Larimar Therapeutics reported a net loss of $29.6 million for Q1 2026, driven by $25.0 million in R&D expenses and $6.1 million in G&A costs, while maintaining a strong liquidity position of $200.4 million in cash and marketable securities. The company bolstered its balance sheet with a $107.6 million equity raise in February 2026, issuing 23 million shares at $5.00 per share, which extends its operational runway into the second quarter of 2027. Regulatory progress remains positive, with the FDA granting Breakthrough Therapy Designation to nomlabofusp in February 2026 and aligning on the use of skin FXN as a surrogate endpoint to support a planned BLA submission in June 2026.

SEC 10-Q•5mo ago